Endometrial cancer | Department of Medicine Blog

Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study

Haight PJ, Sanchez M, Thomas SM, Smitherman C, Cosgrove C, Bae-Jump V, Crafton S, Hacker K, Ko E, Krivak T, Lara O, Moore K, Mullen[...]

By sjmartinez • February 23, 2025

Economic Burden of Endometrial Cancer Associated With Polycystic Ovary Syndrome

Pace L, Markovic D, Buyalos R, Bril F, Azziz R. Economic Burden of Endometrial Cancer Associated With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2024[...]

By sjmartinez • August 7, 2024

A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer

Cristea MC, Stewart D, Synold T, Ruel N, Mortimer J, Wang E, Jung A, Wilczynski S, Konecny GE, Eng M, Kilpatrick L, Han E, Dellinger[...]

By sjmartinez • March 25, 2024